Objective Response by mRECIST to Initial Lenvatinib Therapy Is an Independent Factor Contributing to Deep Response in Hepatocellular Carcinoma Treated with Lenvatinib-Transcatheter Arterial Chemoembolization Sequential Therapy

OBJECTIVE: There is limited information regarding the benefits of Lenvatinib-transcatheter arterial chemoembolization (LEN-TACE) sequential therapy for unresectable hepatocellular carcinoma (u-HCC). We compared the efficacy and safety of LEN-TACE sequential therapy to LEN monotherapy and investigate...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuroda, Hidekatsu, Oikawa, Takayoshi, Ninomiya, Masashi, Fujita, Masashi, Abe, Kazumichi, Okumoto, Kazuo, Katsumi, Tomohiro, Sato, Wataru, Igarashi, Go, Iino, Chikara, Endo, Tetsu, Tanabe, Nobukazu, Numao, Hiroshi, Fukuda, Shinsaku, Iijima, Katsunori, Masamune, Atsushi, Ohira, Hiromasa, Ueno, Yoshiyuki, Takikawa, Yasuhiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9294936/
https://www.ncbi.nlm.nih.gov/pubmed/35978602
http://dx.doi.org/10.1159/000522424

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9294936/
https://www.ncbi.nlm.nih.gov/pubmed/35978602
http://dx.doi.org/10.1159/000522424

Ejemplares similares